Gene therapy for SMA tested in real-world settings of poorer nations
Disease control
Recruiting now
This study is testing a gene therapy called vesemnogene lantuparvovec for spinal muscular atrophy (SMA) in low- and middle-income countries. Researchers will track safety and whether children reach motor milestones like sitting or walking. The trial involves 15 participants and a…
Phase: PHASE3 • Sponsor: Lantu Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC